Retargeting vesicular stomatitis virus glycoprotein pseudotyped lentiviral vectors with enhanced stability by in situ synthesized polymer shell

Human Gene Therapy Methods

Volumn 24, Issue 1, 2013, Pages 11-18

  Liang, Min ^a,b   Yan, Ming ^a,b   Lu, Yunfeng ^a   Chen, Irvin S Y ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS PROTEIN; VIRUS PROTEIN;

ARTICLE; CELL SURFACE; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENCAPSULATION; ENDOCYTOSIS; FREEZE THAWING; GENE TARGETING; HELA CELL; HOST CELL; HUMAN; MOLECULAR RECOGNITION; NANOTECHNOLOGY; NANOVIRUS; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN STABILITY; REACTION TIME; REVERSE TRANSCRIPTION; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTIVITY;

GENETIC THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; LENTIVIRUS; MEMBRANE GLYCOPROTEINS; NANOTECHNOLOGY; NANOVIRUS; PEPTIDES, CYCLIC; POLYMERS; TRANSDUCTION, GENETIC; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS;

LENTIVIRUS; NANOVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84878272632     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.113     Document Type: Article

References (39)

1. Aiuti, A., Slavin, S., Aker, M., et al. (2002). Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413.
2. Aiuti, A., Cattaneo, F., Galimberti, S., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. New Engl. J. Med. 360, 447-458.
3. Akkina, R.K., Walton, R.M., Chen, M.L., et al. (1996). Highefficiency gene transfer into CD34 + cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70, 2581-5.
4. Beebe, D.P., and Cooper, N.R. (1981). Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J. Immunol. 126, 1562-8.
5. Burns, J.C., Friedmann, T., Driever, W., et al. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90, 8033-7.
6. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-23.
7. Cavazzana-Calvo, M., Hacein-Bey, S., De Saint Basile, G., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672.
8. Croyle, M.A., Yu, Q.C., and Wilson, J.M. (2000). Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 11, 1713-22.
9. Croyle, M.A., Callahan, S.M., Auricchio, A., et al. (2004). PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78, 912-21.
10. Depolo, N.J., Reed, J.D., Sheridan, P.L., et al. (2000). VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol. Ther. 2, 218-22.
11. Giordano, F., Sorg, U., Appelt, J., et al. (2011). Clonal inventory screens uncover monoclonality following serial transplantation of MGMT P140K-transduced stem cells and dose-intense chemotherapy. Hum. Gene Ther. 22, 697-710.
12. Han, X., Kasahara, N., and Kan, Y.W. (1995). Ligand-directed retroviral targeting of human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 92, 9747-9751.
13. Haywood, A.M. (1994). Virus receptors: binding, adhesion strengthening, and changes in viral structure. J. Virol. 68, 1-5.
14. Kasahara, N., Dozy, A., and Kan, Y. (1994). Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266, 1373-1376.
15. Kreppel, F., and Kochanek, S. (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. 16, 16-29.
16. Lee, G.K., Maheshri, N., Kaspar, B., and Schaffer, D.V. (2005). PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol. Bioeng. 92, 24-34.
17. Liang, M., Morizono, K., Pariente, N., Kamata, M., et al. (2009a). Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway. J. Virol. 83, 13026-31.
18. Liang, M., Pariente, N., Morizono, K., and Chen, I. (2009b). Targeted transduction of CD34 + hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells. Journal of Gene Medicine 11, 185-96.
19. Marin, M., Noel, D., Valsesia-Wittman, S., et al. (1996). Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J. Virol. 70, 2957-2962.
20. Marsh, M., and Helenius, A. (1989). Virus entry into animal cells. Adv. Virus Res. 36, 107-51.
21. Mitra, A., Mulholland, J., Nan, A., et al. (2005). Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J. Control Release 102, 191-201.
22. Morizono, K., and Chen, I. (2005). Targeted gene delivery by intravenous injection of retroviral vectors. Cell Cycle 4, 854-6.
23. Morizono, K., Bristol, G., Xie, Y., et al. (2001). Antibody-directed targeting of retroviral vectors via cell surface antigens. J. Virol. 75, 8016-8020.
24. Morizono, K., Xie, Y., Ringpis, G., et al. (2005). Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 11, 346-352.
25. Morizono, K., Ringpis, G., Pariente, N., et al. (2006). Transient low pH treatment enhances infection of lentiviral vector pseudotypes with a targeting Sindbis envelope. Virol. 10, 71-81.
26. Morizono, K., Pariente, N., Xie, Y., and Chen, I. (2009). Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J. Gene Med. 11, 549-58.
27. Morizono, K., Ku, A., Xie, Y., et al. (2010). Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J. Virol. 84, 6923-34.
28. Morizono, K., Xie, Y., Olafsen, T., et al. (2011). The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe. 9, 286-98.
29. Muller-Sieburg, C., Cho, R., Karlsson, L., et al. (2004). Myeloidbiased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. Blood 103, 4111-8.
30. Muller-Sieburg, C., Sieburg, H., Bernitz, J., and Cattarossi, G. (2012). Stem cell heterogeneity: implications for aging and regenerative medicine. Blood 119, 3900-7.
31. Nilson, B., Morling, F., Cosset, F., and Russell, S. (1996). Targeting of retroviral vectors through protease-substrate interactions. Gene Ther. 3, 280-286.
32. Pariente, N., Morizono, K., Virk, M., et al. (2007). A novel dualtargeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol. Ther. 15, 1973-1981.
33. Pariente, N., Mao, S., Morizono, K., and Chen, I. (2008). Efficient targeted transduction of primary human endothelial cells with dual-targeted lentiviral vectors. J. Gene Med. 10, 242-8.
34. Shuhendler, A.J., Prasad, P., Leung, M., et al. (2012). A novel solid lipid nanoparticle formulation for active targeting to tumor alpha(v) beta(3) integrin receptors reveals cyclic RGD as a double-edged sword. Adv. Healthc. Mater. 1, 600-8.
35. Somia, N.V., Zoppe, M., and Verma, I.M. (1995). Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc. Natl. Acad. Sci. U.S.A. 92, 7570-7574.
36. Valsesia-Wittmann, S., Drynda, A., Deleage, G., et al. (1994). Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 68, 4609-4619.
37. Yan, M., Ge, J., Liu, Z., and Ouyang, P. (2006). Encapsulation of single enzyme in nanogel with enhanced biocatalytic activity and stability. J. Am. Chem. Soc. 128, 11008-9.
38. Yan, M., Du, J., Gu, Z., et al. (2010). A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat. Nanotech. 5, 48-53.
39. Yu, J.H., and Schaffer, D.V. (2005). Advanced targeting strategies for murine retroviral and adeno-associated viral vectors. Adv. Biochem. Eng. Biotechnol. 99, 147-67.